Comprehensive health management method and device for diabetes and fatty liver co-disease management

By constructing a multi-dimensional comprehensive health risk assessment model, the problem of insufficient comprehensive risk assessment for patients with diabetes and fatty liver is solved, and a comprehensive health risk assessment and personalized follow-up plan for patients with diabetes and fatty liver is achieved, which improves management efficiency.

CN118899082APending Publication Date: 2024-11-05ZHEJIANG UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410919771.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing technology lacks a multi-dimensional comprehensive health risk assessment and management method for patients with diabetes and fatty liver, resulting in the incomplete risk assessment and ineffective distinction between patient risk levels and stratified management.

Method used

By constructing a multi-dimensional comprehensive health risk evaluation model including demographics, disease progression and management effects, patient health data are collected, comprehensive health risk values ​​are calculated, and a personalized follow-up plan is formulated based on the risk level to improve management effectiveness.

Benefits of technology

A comprehensive and accurate health risk assessment for patients with diabetes and fatty liver has been achieved, ensuring continuous tracking and timely management of key indicators, and improving the management efficiency of medical staff and the health management effect of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118899082A_ABST
    Figure CN118899082A_ABST
Patent Text Reader

Abstract

The invention discloses a comprehensive health management method and device for diabetes and fatty liver co-disease management. The device comprises a health data acquisition terminal, a doctor terminal and a patient terminal which are respectively communicated with a cloud server, the health data acquisition terminal acquires health detection data of a patient; the cloud server further divides a plurality of risk evaluation indexes in dimensions including demology, disease progression and management effect by constructing a comprehensive health risk evaluation model, performs patient risk grading according to a calculated comprehensive health risk value, and generates a patient follow-up plan; the doctor end is used for checking patient risk evaluation conditions and adjusting and modifying follow-up visit plans; and the patient end is used for checking risk evaluation conditions and follow-up visit plans. According to the method, multi-dimensional health risk evaluation can be carried out on the diabetic fatty liver co-disease management patient, the health risk is quantified, then a personalized follow-up monitoring plan is made, the effect and efficiency of comprehensive health management on the diabetic fatty liver patient are improved, and the method has important clinical significance and practical value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical health management technology, and specifically relates to a comprehensive health management method and device for the management of comorbidities of diabetes and fatty liver. Background Art

[0002] With the aging of the population and changes in lifestyle, diabetes and chronic liver disease have gradually become prevalent chronic diseases, among which type 2 diabetes (hereinafter referred to as diabetes) and non-alcoholic fatty liver disease (hereinafter referred to as fatty liver) are the main types of diseases. Diabetes and fatty liver are closely related. Fatty liver not only increases the risk of diabetes, but also accelerates the progression of various diabetes-related target organ damage in diabetic patients. Diabetes will also increase the risk of fatty liver and accelerate the progression of liver lesions. Patients with both diabetes and fatty liver have more difficult to control blood sugar, are more likely to develop cardiovascular and cerebrovascular diseases and related target organ damage, and have a significantly increased risk of poor prognosis.

[0003] Diabetes and fatty liver disease not only share common risk factors, but the treatments for the two diseases are also similar, which gave rise to the concept of co-management of diabetes and fatty liver disease, that is, the joint management and treatment of diabetes and fatty liver disease. The treatment and management of patients with fatty liver disease cannot be limited to simple liver disease, but also requires an assessment of the risks associated with diabetes and appropriate treatment. Most diabetic patients also have fatty lesions in the liver, so diabetic patients are not limited to endocrinologists, but also need to consider the prevention and treatment of fatty liver disease. Co-management of diabetes and liver disease is not only expected to help more patients break the vicious cycle of poor blood sugar control and achieve better treatment effects of protecting the liver and stabilizing blood sugar, but also reduce the risk of other diseases caused by diabetes combined with fatty liver disease, further reduce the risk of complications such as chronic kidney disease, cardiovascular and cerebrovascular diseases, and coronary artery disease, and reduce the possibility of severe illness.

[0004] However, the current management and treatment of patients with diabetes and fatty liver is still based on a specialist diagnosis and treatment model. In this model, doctors usually treat diabetes and fatty liver as two independent and unrelated diseases, and the health risk assessment and treatment of patients are often limited to one of the diseases. In addition, the risk assessment and stratification of patients are usually based on the clinical guidelines for single diseases of diabetes or fatty liver. However, the single disease assessment method is not comprehensive enough when applied to the assessment of patients with diabetic liver.

[0005] The Chinese patent application with publication number CN115691811A provides a health management method and system for patients with type 2 diabetes. It uses health data of dimensions such as age, height, weight, blood pressure, heart rate, blood sugar and eating habits to build a database, and searches for similar health data of other patients in the database based on the physical data input by the patient to determine the patient's risk status and generate health management suggestions. However, the risk identification of this method depends on the existing patient database. The scale and accuracy of the data will affect the risk identification of patients. In addition, the risk classification of existing patients is limited to two levels: risk or no risk, and the dimensions of risk assessment are relatively few, which cannot effectively distinguish patients.

[0006] The Chinese patent application with publication number CN116626275A provides a prognosis risk assessment system and application for severe liver fibrosis associated with metabolic-related fatty liver, and performs risk assessment by establishing a prognosis prediction model for severe liver fibrosis. However, the system uses liver fibrosis as a poor prognosis outcome to calculate the patient's health risk. However, in the management of patients with diabetes and fatty liver, the patient's poor prognosis outcomes include not only liver fibrosis, but also target organ damage, cardiovascular and cerebrovascular diseases, and other diseases that are common in patients with diabetes and fatty liver. Therefore, the risk evaluation indicators in this patent application are not comprehensive enough and are not suitable for risk assessment and health management of patients with diabetes and fatty liver.

[0007] Therefore, there is currently a lack of a multi-dimensional comprehensive health risk assessment and management method for patients with diabetes and fatty liver. Summary of the invention

[0008] In view of the above, the purpose of the present invention is to provide a comprehensive health management method and device for the management of diabetic fatty liver comorbidity, which can establish a multi-dimensional health risk comprehensive evaluation model for patients with diabetic fatty liver comorbidity management and quantify health risks, realize risk ranking and risk level division, and formulate personalized follow-up plans according to risk levels, thereby improving the comprehensive health management effect of diabetic liver patients, which has important clinical significance and practical value.

[0009] In order to achieve the above-mentioned invention object, the technical solution provided by the present invention is as follows:

[0010] An embodiment of the present invention provides a comprehensive health management device for the management of diabetic fatty liver comorbidities, comprising: a health data collection terminal, a doctor terminal and a patient terminal, each of which communicates with a cloud service terminal;

[0011] The health data collection terminal is used to identify the patient and collect the patient's health test data and upload it to the cloud service end;

[0012] The cloud service end is used to store patient health test data and follow-up plan rules; it is also used to construct a comprehensive health risk evaluation model, further divide a number of risk evaluation indicators and their calculation methods in the dimensions of demography, disease progression and management effect, and calculate the risk evaluation indicator data based on the health test data and the risk evaluation indicators, and then obtain the risk score by grading and scoring, and calculate the risk score by multi-dimensional weighted calculation to obtain the comprehensive health risk value, and then perform patient risk grading according to the comprehensive health risk value; it is also used to generate a patient follow-up plan according to the follow-up plan rules and patient risk grading;

[0013] The doctor end is used to view the patient risk assessment index data, comprehensive health risk value and risk classification, and adjust and modify the patient follow-up plan based on actual conditions and update it to the cloud service end;

[0014] The patient terminal is used to view risk assessment indicator data, comprehensive health risk values, risk grading, and adjusted follow-up plans, and upload measurement data that needs to be uploaded by the patient in the risk assessment indicators.

[0015] Preferably, the risk assessment indicators and their calculation methods are further divided into several risk assessment indicators and their calculation methods based on the dimensions of demography, disease progression and management effect, including:

[0016] In the demographic dimension, the risk assessment indicators include: age, body mass index, abdominal obesity, disease history and family history;

[0017] In terms of disease progression, the risk assessment indicators include: risk level of fatty liver, blood lipid level, renal function level, liver function level, insulin resistance and complications;

[0018] In terms of management effectiveness, risk assessment indicators include: weight control, blood sugar control, exercise control and diet control.

[0019] Preferably, the calculation method of the risk assessment indexes for age, body mass index, abdominal obesity, disease history and family history includes:

[0020] Age: The age range is determined based on the patient’s actual age;

[0021] Body mass index: BMI, BMI = weight (kg) / height 2 (m 2 ), patients were divided into different levels including thin, normal, overweight and obese according to BMI;

[0022] Abdominal obesity: Use a measuring tool to measure the patient's waist circumference, and determine whether the patient has abdominal obesity based on whether the waist circumference meets the abdominal obesity standard;

[0023] Medical history: by asking the patient or checking the medical records, find out whether the patient has had any diseases including hypertension, hyperlipidemia, gout, cardiovascular and cerebrovascular diseases and chronic liver disease in the past;

[0024] Family history: Ask the patient whether there is a history of diseases in his or her family, including liver cancer, cirrhosis, and diabetes.

[0025] Preferably, the calculation method for the risk level of fatty liver, blood lipid level, renal function level, liver function level, insulin resistance and complications includes:

[0026] Risk level of fatty liver: According to the liver fat content and the degree of liver fibrosis progression, the patient's risk level of fatty liver is divided into low risk, medium risk, high risk and very high risk;

[0027] Blood lipid level: Blood lipid test results including low-density lipoprotein, triglycerides and total cholesterol are used to determine whether the patient has abnormal blood lipid levels;

[0028] Renal function level: Blood test results of renal function indicators including uric acid, creatinine and blood urea nitrogen are used to determine whether the patient has abnormal renal function level;

[0029] Liver function level: The liver function index blood test results including alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase are used to determine whether the patient has abnormal liver function level;

[0030] Insulin resistance: The insulin resistance index is calculated based on the blood test results of insulin indicators including fasting blood glucose and fasting insulin levels using the formula: fasting blood glucose (mmol / L)*fasting insulin (μU / mL) / 22.5. The insulin resistance index is used to determine whether the patient has insulin resistance.

[0031] Complications: By questioning the patient, reviewing medical records or conducting relevant examinations, we can find out whether the patient has complications including cardiovascular and cerebrovascular diseases, diabetic retinopathy and diabetic foot.

[0032] Preferably, the calculation method for weight control, blood sugar control, exercise control and diet control includes:

[0033] Weight control: Based on the weight measurement data uploaded by the patient in the previous management cycle, the actual weight loss per month is compared with the monthly target weight loss. If the actual weight loss reaches or exceeds the target weight loss, the output is "reached", and if the target weight loss is not reached, the output is "failed". The monthly target weight loss is calculated based on the patient's body mass index, risk level of fatty liver, liver function level and weight.

[0034] Blood sugar control: Calculate the blood sugar compliance rate based on the blood sugar measurement data uploaded by the patient in the previous management cycle. The blood sugar compliance rate is the ratio of the number of blood sugar compliance times to the total number of blood sugar measurements. If the blood sugar compliance rate reaches or exceeds the preset standard, it is judged that blood sugar control is met. Otherwise, it is judged that blood sugar control is not met. The target blood sugar value for blood sugar compliance includes fasting blood sugar value and random blood sugar value, which are calculated based on the patient's complications and age.

[0035] Exercise control: Based on the exercise data uploaded by the patient in the previous management cycle, the average daily exercise duration is compared with the daily target exercise duration. If the average daily exercise duration reaches the target exercise duration, the output is "reaching the standard", otherwise, the output is "not reaching the standard". The daily target exercise duration is the ratio of the recommended daily calorie consumption to body weight. The recommended daily calorie consumption is set based on whether there is insulin resistance.

[0036] Dietary control: Dietary control is measured by the intake compliance rate, that is, the comparison between the average actual daily intake and the target daily intake. If the average actual daily intake is lower than the target daily intake, the output is met; otherwise, the output is not met. The target daily intake is calculated by multiplying the ideal body weight and the calories required per unit body weight. The ideal body weight is set according to height, and the calories required per unit body weight is set according to body mass index.

[0037] Preferably, the risk assessment index data is calculated based on the health detection data and the risk assessment index, and then the risk score is obtained by grading and assigning points, including:

[0038] The health check data of the patients are summarized, and the risk assessment index data is calculated by combining the risk assessment index and its calculation method. The risk assessment index data is graded and scored to obtain the risk score corresponding to each risk assessment index data of each patient.

[0039] Preferably, the risk score is calculated through multi-dimensional weighted calculation to obtain a comprehensive health risk score, including:

[0040] After obtaining the risk scores corresponding to all risk assessment indicator data of each patient, the risk scores are weighted and summed according to the dimensions of demography, disease progression and management effect to which the different risk assessment indicator data belong to to obtain the health risk score of each dimension. The calculation formula is as follows:

[0041]

[0042] Among them, Score ij represents the health risk score of the jth dimension of the i-th patient, m represents the number of risk assessment indicator data contained in this dimension, and score(k) represents the risk score corresponding to the k-th risk assessment indicator data;

[0043] Then, the weighted sum of the health risk scores of each dimension is calculated to obtain the comprehensive health risk value. The calculation formula is as follows:

[0044] Score i =λ1Score i1 +λ2Score i2 +λ3Score i3

[0045] Among them, Score i represents the comprehensive health risk value of the i-th patient, Score i1 、Score i2 and Score i3 represent the health risk scores of the i-th patient in the demographic dimension, disease progression dimension, and management effect dimension respectively, and λ1, λ2, and λ3 represent weight values ​​whose sum is 1.

[0046] Preferably, patient risk stratification is performed based on a comprehensive health risk value, including:

[0047] The calculated comprehensive health risk values ​​of all patients are sorted according to the scores, and the risk level of each patient is divided into high risk level, medium risk level and low risk level by setting thresholds.

[0048] Preferably, generating a patient follow-up plan according to the follow-up plan rules and the patient risk classification includes:

[0049] The follow-up plan rules include indicator categories, follow-up indicators and follow-up frequency; among them, indicator categories include basic indicators, biochemical indicators and imaging indicators. The follow-up indicators of basic indicators include body weight, blood sugar, dietary intake and exercise volume. The follow-up indicators of biochemical indicators include blood test-related indicators of liver function, blood lipids and kidney function. The follow-up indicators of imaging indicators include liver fat content, fatty liver progression and complications. The follow-up frequency is set according to different follow-up indicators and patient risk classification to obtain a follow-up plan for each patient.

[0050] To achieve the above-mentioned purpose of the invention, the embodiment of the present invention further provides a comprehensive health management method for the management of diabetic fatty liver comorbidity, which is implemented by using the above-mentioned comprehensive health management device for the management of diabetic fatty liver comorbidity, and includes the following steps:

[0051] Use the health data collection terminal to identify the patient and collect the patient's health test data and upload it to the cloud service end;

[0052] The cloud server is used to store patient health test data and follow-up plan rules; by constructing a comprehensive health risk evaluation model, a number of risk evaluation indicators and their calculation methods are further divided in the dimensions of demography, disease progression and management effect, and the risk evaluation indicator data is calculated based on the health test data and risk evaluation indicators, and then the risk score is obtained by grading and scoring, and the risk score is calculated by multi-dimensional weighted calculation to obtain a comprehensive health risk value, and then the patient risk is graded according to the comprehensive health risk value; the patient follow-up plan is generated according to the follow-up plan rules and patient risk grading;

[0053] Use the doctor's end to view the patient's risk assessment index data, comprehensive health risk value and risk classification, and adjust and modify the patient's follow-up plan based on actual conditions and update it to the cloud service end;

[0054] Use the patient end to view risk assessment indicator data, comprehensive health risk values, risk grading, and adjusted follow-up plans, and upload measurement data that needs to be uploaded by the patient in the risk assessment indicators.

[0055] Compared with the prior art, the present invention has the following beneficial effects:

[0056] The present invention collects data through the health data collection terminal and the patient end, and constructs a comprehensive health risk evaluation model for patients with diabetic fatty liver comorbidity management on the cloud service end, which can systematically integrate and analyze the multi-dimensional health data of patients, calculate the comprehensive health risk value of patients and sort them by grade, thereby dividing the risk level of patients and achieving a comprehensive and accurate evaluation of the comprehensive health risk of patients. At the same time, the present invention can formulate targeted follow-up plans for patients with different risk levels, ensure that key indicators can be tracked continuously and timely, realize stratified management of patients, and improve the management efficiency of medical staff on patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0058] Figure 1 It is a schematic diagram of the structure of a comprehensive health management device for managing diabetic fatty liver comorbidities provided by an embodiment of the present invention;

[0059] Figure 2 It is a flow chart of a comprehensive health management method for managing diabetic fatty liver comorbidities provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0060] To make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific implementation methods described herein are only used to explain the present invention and do not limit the scope of protection of the present invention.

[0061] The inventive concept of the present invention is: in view of the problems in the prior art that the risk assessment of patients with diabetes and fatty liver in the co-management of diabetes and fatty liver is not comprehensive enough, and there is a lack of methods for quantifying health risks, distinguishing risk levels and stratified management, the embodiments of the present invention provide a comprehensive health management method and device for the co-morbidity management of diabetes and fatty liver. Based on clinical guidelines, expert opinions and clinical practice experience, multiple dimensions of health risk assessment and corresponding risk assessment indicators are determined, and then a comprehensive risk assessment model is constructed by adopting a multi-dimensional comprehensive evaluation method. By separately evaluating the three dimensions of demography, disease progression and management effect, and summarizing the evaluation results of each dimension to obtain a comprehensive health risk value, a comprehensive evaluation of the overall health status and risk grading are achieved. Finally, a follow-up rule library is constructed, which can formulate targeted follow-up plans according to the patient's health risk level, thereby improving the effect and efficiency of comprehensive health management of patients.

[0062] Figure 1 Schematic diagram of the structure of a comprehensive health management device for managing diabetic fatty liver comorbidity provided by an embodiment of the present invention. Figure 1 As shown, the embodiment provides a comprehensive health management device 100 for managing the comorbidity of diabetes and fatty liver, including: a health data collection terminal 110, a doctor terminal 130 and a patient terminal 120 that communicate with a cloud service terminal 140 respectively.

[0063] The health data collection terminal 110 includes a patient identification module and a data collection and upload module. The patient identification module is used to identify the patient's identity; the data collection and upload module is used to collect the patient's health test data and upload it to the cloud service terminal 140. In the embodiment, the health data collection terminal 110 includes an office computer, a mobile terminal, and a health data detection device used by the hospital to measure health indicators, such as a blood analysis device and an ultrasonic examination instrument.

[0064] The cloud service end 140 includes a database module, a health risk assessment module and a follow-up plan generation module. Among them, the database module includes a hardware data storage device of a patient health database and a follow-up plan library, the patient health database is used to store patient health test data, patient personal information and various risk assessment indicator data, and the follow-up plan library is used to store follow-up plan rules, specifically including the patient's follow-up indicator category, follow-up indicator, follow-up frequency and the latest measurement date; the health risk assessment module includes a processor for running health risk calculation, and a health risk comprehensive evaluation model is constructed based on the selected risk assessment indicators. Specifically, a number of risk assessment indicators and their calculation methods are further divided in the dimensions including demography, disease progression and management effect, and the risk assessment indicator data is calculated according to the health test data and the risk assessment indicator, and then the risk score is obtained by grading and assigning points, and the risk score is calculated by multi-dimensional weighted calculation to obtain a comprehensive health risk value, and then the risk ranking and patient risk grading are performed according to the comprehensive health risk value; the follow-up plan generation module includes a processor for running the follow-up plan generation, and according to the received patient risk level result, by querying the follow-up plan rules, a targeted follow-up plan is formulated, including follow-up indicators and follow-up frequency.

[0065] The doctor side 130 includes a patient management module, a health risk result analysis module, and a follow-up plan formulation module. The doctor side 130 can support doctors or managers to access the data of the cloud service side 140 on computer devices. After obtaining data access rights, they can upload, modify and obtain the health data of patients with diabetes and fatty liver who participate in the management. Among them, the patient management module is used to view the risk assessment index data of each patient, including three dimensions: demography, disease progression, and management effect; the health risk result analysis module is used to view the patient's comprehensive health risk value and risk classification, so that doctors can intuitively understand the patient's health risk level; the follow-up plan formulation module is used to formulate follow-up plans for patients with different risk levels, including follow-up indicators and the collection frequency of each indicator. Doctors can adjust and modify the generated follow-up plan based on actual conditions and update it to the cloud service side 140.

[0066] The patient end 120 includes a risk result viewing module, a follow-up plan viewing module, and an indicator upload module. The patient end 120 supports patients to log in to the WeChat applet using their registered mobile phone number, view their health risk level and follow-up plan, upload indicator monitoring values ​​on time, and complete follow-up examination content. Among them, the risk result viewing module is used to view risk assessment indicator data, comprehensive health risk values, and risk classification. It also supports viewing the risk score corresponding to each risk assessment indicator data. The system provides personalized guidance to patients based on abnormal indicators; the follow-up plan viewing module is used to view the adjusted and modified patient follow-up plan. The system calculates the next measurement date of each follow-up indicator based on the follow-up frequency of each follow-up indicator and the most recent measurement date, and reminds patients to complete the indicator upload and follow-up examination on time; the indicator upload module is used for patients to upload to the cloud server 140 the measurement data that needs to be uploaded by patients themselves in the risk assessment indicators except for the patient health test data, including the measurement data of various test indicators uploaded by patients during self-management, including weight control, blood sugar control, exercise control and diet control, and also includes patients uploading indicators in a timely manner according to the follow-up plan, completing the follow-up content, and regularly updating the health risk assessment results.

[0067] Specifically, based on the comprehensive health management device 100 for the management of diabetes and fatty liver comorbidity provided by the embodiment of the present invention, the process of collecting data on patients with diabetes and fatty liver target management in the co-management of diabetes and fatty liver and obtaining the health risk assessment results of the patients to achieve comprehensive health management of the enrolled patients is specifically described. In the embodiment, fatty liver is defined by the following criteria: liver ultrasound results show punctate hyperechoic liver parenchyma, backfield echo attenuation, and unclear intrahepatic vessels; diabetes is defined by one of the following criteria: (1) current insulin treatment and / or use of oral hypoglycemic drugs; (2) serum glucose level ≥11.1mmol / L (200mg / dl); (3) glycosylated hemoglobin ≥6.5%.

[0068] 1. Division and calculation method of risk assessment indicators

[0069] Diabetes and fatty liver are closely related and are risk factors for each other. When both occur at the same time, they will accelerate the progression of the disease, making patients more susceptible to cardiovascular and cerebrovascular diseases, and significantly increasing the risk of poor prognosis. The target management population for co-management of diabetes and liver disease includes patients diagnosed with fatty liver or diabetes, or both. Therefore, when conducting health risk assessment, assessment indicators related to diabetes, fatty liver, and metabolic risks need to be taken into account. Through research from relevant clinical guidelines and expert consensus on fatty liver and diabetes, as well as hospital clinical practice experience, and interviews with doctors in related fields, a total of 15 risk assessment indicators were screened, and these indicators were divided into three dimensions: demography, disease progression, and management effect. Among them, the risk assessment indicators of demography and disease progression require that the doctor or manager upload the risk assessment indicators through the doctor terminal 130 or the health data collection terminal 110 after the patient has been examined in the hospital, and the risk assessment indicators of the management effect dimension are uploaded by the patient through the patient terminal 120 during the self-management process.

[0070] The first dimension is demography, including age, body mass index (BMI), abdominal obesity, medical history, and family history. The following are the evaluation indicators, selection basis, and calculation method selected from the demography dimension.

[0071] (1) Age:

[0072] Selection basis: With age, the body's metabolic function gradually declines and the body's resistance to disease weakens. Therefore, older patients have a relatively higher risk of metabolic complications such as cardiovascular and cerebrovascular diseases.

[0073] Calculation method: During the assessment, the patient's actual age is used to determine the age range and perform risk stratification.

[0074] (2) BMI:

[0075] Selection basis: BMI is a commonly used indicator to measure the degree of human obesity. It is closely related to the occurrence of metabolic-related diseases such as diabetes and fatty liver. Overweight and obese patients are more likely to experience disease exacerbation. Therefore, BMI is an important reference factor for assessing patient risks.

[0076] Calculation method: BMI = weight (kg) / height 2 (m 2 ), and the patients were divided into different levels such as thin, normal, overweight and obese according to BMI.

[0077] (3) Abdominal obesity:

[0078] Selection basis: Abdominal obesity is one of the important characteristics of metabolic syndrome and is closely related to the occurrence of metabolic-related diseases such as diabetes and fatty liver. Waist circumference is a common indicator for measuring the degree of abdominal obesity and is of great significance for predicting the risk of patients developing metabolic-related diseases.

[0079] Calculation method: Use a measuring tool to measure the patient's waist circumference, and determine whether the patient has abdominal obesity based on whether the waist circumference reaches the abdominal obesity standard. In the embodiment, according to the latest guidelines, the standard for abdominal obesity is: waist circumference for men ≥ 90 cm (female ≥ 80 cm).

[0080] (4) Medical history:

[0081] Selection basis: The patient's previous medical history is an important reference factor for assessing their current disease risk. Hypertension, hyperlipidemia, gout and other diseases are closely related to the occurrence of metabolic-related diseases. Patients with a history of these diseases are more likely to experience disease exacerbation.

[0082] Calculation method: By asking the patient or checking the medical records, find out whether the patient has a history of hypertension, hyperlipidemia, gout, cardiovascular and cerebrovascular disease, chronic liver disease, etc., and record it.

[0083] (5) Family history:

[0084] Selection basis: Genetic factors play an important role in the occurrence of metabolic-related diseases. Patients with a family history of liver cancer, cirrhosis, diabetes, etc. have a relatively high risk of developing metabolic-related diseases;

[0085] Calculation method: Ask the patient whether there is a history of liver cancer, cirrhosis, diabetes and other diseases in his family, and record it.

[0086] The second dimension is disease progression, which directly reflects the severity and development trend of the disease, including the risk level of fatty liver, blood lipid levels, renal function levels, liver function levels, insulin resistance and complications. The following is the selection basis, calculation and grading method of each evaluation indicator in the disease progression dimension.

[0087] (1) Danger level of fatty liver:

[0088] Selection basis: The risk level of fatty liver is the main concern of the severity of the disease in patients with diabetic liver disease, and is closely related to the liver fat content and the degree of liver fibrosis progression. These two indicators are obtained from the ultrasonic attenuation parameter (UAP) and liver stiffness (LSM) in the test results of liver transient elasticity detection technology;

[0089] Calculation method:

[0090]

[0091] In the embodiments, UAP≤244db / m represents mild liver fat content, UAP>244db / m represents moderate or severe liver fat content, LSM<15kPa represents no liver fibrosis, 15kPa≤LSM≤20kPa represents combined with advanced liver fibrosis, and LSM>20kPa represents combined with severe liver fibrosis or cirrhosis.

[0092] (2) Blood lipid levels:

[0093] Selection basis: Abnormal blood lipid level is one of the important characteristics of metabolic-related diseases and is closely related to the occurrence of cardiovascular and cerebrovascular diseases, fatty liver and other diseases. Assessing blood lipid levels helps to understand the patient's metabolic status and risk level;

[0094] Calculation method: Through blood tests, the patient's low-density lipoprotein (LDL), triglycerides (TG), total cholesterol (TC) and other blood lipid indicators are measured. If any of these indicators exceeds the upper limit of the normal range, it is judged that the blood lipid level is abnormal, that is:

[0095]

[0096] (3) Renal function level:

[0097] Selection basis: Abnormal renal function is one of the common complications of metabolic-related diseases and is closely related to diseases such as diabetes and hypertension. Assessing the level of renal function helps to understand the patient's overall health status and risk level;

[0098] Calculation method: Through blood tests, the patient's uric acid (UA), creatinine (Cr), blood urea nitrogen (BUN) and other indicators are measured. If there are values ​​outside the normal range of these indicators, it is judged that the renal function level is abnormal, that is:

[0099]

[0100] (4) Liver function level:

[0101] Selection basis: Abnormal liver function is one of the common manifestations of metabolic-related diseases and is closely related to diseases such as fatty liver and hepatitis. Assessing liver function levels helps to understand the patient's liver health status and risk level;

[0102] Calculation method: Through blood tests, the patient's alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) and other liver function indicators are measured. If there are values ​​outside the normal range of these indicators, it is judged that the liver function level is abnormal, that is:

[0103]

[0104] (5) Insulin resistance:

[0105] Selection basis: Insulin resistance is one of the important pathophysiological characteristics of metabolic-related diseases and is closely related to the occurrence of diseases such as diabetes and fatty liver. Assessing insulin resistance helps to understand the patient's metabolic status and risk level;

[0106] Calculation method: Through blood tests, the patient's fasting blood glucose (FPG) and fasting insulin levels are measured, and the insulin resistance index (HOMA-IR) is calculated using the formula: fasting blood glucose (FPG, mmol / L) * fasting insulin (μU / mL) / 22.5. Based on the value of HOMA-IR, it is determined whether the patient has insulin resistance.

[0107] (6) Complications:

[0108] Selection basis: Metabolic-related diseases are often accompanied by a variety of complications, such as cardiovascular and cerebrovascular diseases, diabetic retinopathy, diabetic foot, etc. The emergence of these complications further increases the risk level and treatment difficulty of patients;

[0109] Calculation method: By asking patients, checking medical records or conducting relevant examinations, we can find out whether the patients have complications such as cardiovascular and cerebrovascular diseases, diabetic retinopathy, and diabetic foot.

[0110] The third dimension is the patient's management effect, including weight control, blood sugar control, exercise control and diet control. In the management process of diabetic liver patients, evaluating the management effect is the key to ensuring the continuity and optimization of the treatment effect. For the initial enrolled patients, a one-month management is first carried out, and the management effect is evaluated based on the control of indicators in the first month. The patient management effect is mainly calculated comprehensively based on the control of physiological indicators (weight, blood sugar) and living habits (diet, exercise). The following is the selection basis and calculation method of each indicator in this dimension:

[0111] (1) Weight control:

[0112] Selection basis: Weight is one of the important physiological indicators that reflects the changes in the condition of diabetic liver patients. Effective weight control can significantly improve the patient's metabolic status and reduce the burden on the liver, which is of great significance for the control and treatment of the disease.

[0113] Calculation method: Based on the measurement records uploaded by the patient in the previous management cycle, compare the actual weight loss per month with the monthly target weight loss. If the actual weight loss reaches or exceeds the target weight loss, the output is "reached", and if the target weight loss is not reached, the output is "failed". The monthly target weight loss is calculated based on the patient's BMI, risk level of fatty liver, liver function level, and weight. The calculation rules are as follows:

[0114]

[0115] (2) Blood sugar control:

[0116] Selection basis: Blood sugar level is a key indicator for evaluating the changes in the condition of diabetic liver patients. Good blood sugar control helps slow the progression of the disease and reduce the occurrence of complications.

[0117] Calculation method: According to the blood sugar measurement records uploaded by the patient in the previous management cycle, calculate the blood sugar compliance rate (the ratio of the number of blood sugar compliance times to the number of blood sugar measurements). If the compliance rate reaches or exceeds the preset compliance standard (the blood sugar compliance rate threshold is set to 80% in the embodiment), it is judged that blood sugar control is up to standard, otherwise, it is judged that blood sugar control is not up to standard. Among them, the target blood sugar value (mmol / L) is divided into the target fasting blood sugar value and the target random blood sugar value, which is obtained according to the patient's complications and age. The calculation rules are as follows:

[0118]

[0119] (3) Movement control:

[0120] Selection basis: Exercise is an important way to improve the metabolic status of patients with diabetic liver. Appropriate exercise can increase energy consumption, promote fat metabolism, and reduce the burden on the liver.

[0121] Calculation method: Based on the exercise records uploaded by the patient in the previous management cycle, compare the average daily exercise time with the daily target exercise time. If the average daily exercise time reaches the target exercise time, the output is "reaching the target", otherwise the output is "not reaching the target". The target exercise time is calculated based on the recommended daily calorie consumption and body weight, and the calculation rules are as follows:

[0122] Target exercise time (min) = recommended daily calorie consumption (Kcal) ÷ ​​body weight (kg);

[0123] The recommended daily calorie consumption is defined as follows:

[0124] If insulin resistance exists, the recommended daily calorie consumption is 100Kcal;

[0125] If there is no insulin resistance, the recommended daily calorie consumption is 150Kcal.

[0126] (4) Dietary control:

[0127] Selection basis: Reasonable dietary regulation is the key way for diabetic patients to lose weight. By limiting the intake, body weight can be effectively controlled and the overall health of patients can be improved.

[0128] Calculation method: Dietary control is measured by the intake compliance rate, that is, the comparison between the average daily actual intake and the target daily intake. If the average daily actual intake is lower than the target daily intake, the output is compliance, otherwise the output is non-compliance. The target daily intake is calculated from the ideal body weight and the calories required per unit body weight. The calculation rules are as follows:

[0129] Target daily intake (Kcal) = ideal body weight (kg) × required calories per unit body weight (Kcal);

[0130] Among them, ideal body weight (kg) = height (cm) - 105, and the calories required per unit body weight (Kcal) are defined as follows:

[0131]

[0132] Table 1 shows the indicators, calculation and grading standards of each dimension:

[0133] Table 1 Calculation and grading standards of indicators in each dimension

[0134]

[0135]

[0136] 2. Construction of a multi-dimensional comprehensive health risk assessment model

[0137] (1) Risk score calculation:

[0138] Summarize the health test data of patients, combine the risk assessment indicators and their calculation methods to calculate the risk assessment indicator data, grade and assign points to the risk assessment indicator data, and obtain the risk score corresponding to each risk assessment indicator data of each patient. The graded scoring is achieved by constructing a risk assessment indicator graded scoring table. There are multiple risk assessment indicators in the table. Each risk assessment indicator has multiple grading standards. Each grading standard has different values, and the maximum and minimum scores of each evaluation indicator are the same. When the indicator is within the normal range, the risk score of the indicator is the minimum score; when the indicator is within the abnormal range, the risk score of the indicator increases with the increase of the risk level.

[0139] In the embodiment, as shown in Table 2, each evaluation index is graded and assigned, and the levels are set to multiple. For example, for the risk assessment index of age, it is graded in order of risk from small to large, and is divided into four levels of <35, 35-45, 45-55, and >55, and the score increases with the level. It is stipulated that the maximum value of each evaluation index is 1 and the minimum value is 0. The level of age <35 is regarded as the lowest risk and is assigned a value of 0; the level of >55 is regarded as the highest risk and is assigned a value of 1. Among them, for the setting of the assigned scores at each level, an optional scheme is to set the full score of each evaluation index to 1, the minimum score to 0, and the score calculation formula for the remaining levels is the total score divided by the risk ranking of the level in the index. For example, the risk ranking of 35-45 in the age index is 3, and the score of this level is set to 0.33, and the assigned scores of the age risk assessment index at each level are set to 0, 0.33, 0.66 and 1.

[0140] Table 2 Calculation and grading table of risk assessment indicators

[0141]

[0142]

[0143]

[0144] (2) Calculation of health risk scores in each dimension:

[0145] After obtaining the risk scores corresponding to all risk assessment indicator data of each patient, the risk scores are weighted and summed according to the dimensions of demography, disease progression and management effect to which the different risk assessment indicator data belong to to obtain the health risk score of each dimension. The calculation formula is as follows:

[0146]

[0147] Among them, Score ij represents the health risk score of the jth dimension of the i-th patient, m represents the number of risk assessment indicator data contained in this dimension, and score(k) represents the risk score corresponding to the k-th risk assessment indicator data.

[0148] (3) Calculation of comprehensive health risk value:

[0149] The weighted sum of the health risk scores of each dimension is used to calculate the comprehensive health risk value. The calculation formula is as follows:

[0150] Score i =λ1Score i1 +λ2Score i2 +λ3Score i3

[0151] Among them, Score i represents the comprehensive health risk value of the i-th patient, Score i1 、Score i2 and Score i3 represent the health risk scores of the i-th patient in the demographic dimension, disease progression dimension and management effect dimension respectively, λ1, λ2 and λ3 represent weight values ​​whose sum is 1. In the embodiment, the weight values ​​λ1, λ2 and λ3 of the demographic dimension, disease progression dimension and management effect dimension are set to 0.3, 0.4 and 0.3 respectively.

[0152] 3. Patient risk stratification

[0153] The calculated comprehensive health risk values ​​of all patients are sorted according to the scores, and the risk level of each patient is divided into high risk level, medium risk level and low risk level by setting thresholds.

[0154] Specifically, there are n patients with comprehensive health risk values. These patients are sorted from large to small according to their comprehensive health risk values. The calculation rules for setting the threshold are as follows:

[0155] High risk level threshold Score highrisk :

[0156]

[0157] in, Indicates ranking The combined health risk scores of the patients;

[0158] Medium risk level threshold Score mediumrisk :

[0159]

[0160] The risk level classification rules for enrolled patients are as follows:

[0161]

[0162] Among them, RiskLevel i represents the risk classification of the i-th patient.

[0163] In the embodiment, in order to realize the risk level classification of the enrolled patients, the comprehensive health risk score threshold is calculated according to the comprehensive health risk scores of 100 patients in the hospital, and the results are as follows:

[0164] Score highrisk =0.456

[0165] Score mediumrisk=0.21

[0166] Therefore, the risk level of the enrolled patients is divided as follows:

[0167]

[0168] The system will return the risk level result to the patient end 120, and analyze the abnormal data in the patient's risk assessment indicators. For example, if some indicator data in the risk assessment is abnormally high, the system will give corresponding guidance. The patient can understand his or her risk level and self-management guidance in the risk result viewing module of the patient end 120.

[0169] The system will return the patient's comprehensive health risk value ranking results and the corresponding risk level and display them on the health risk result analysis module interface of the doctor end 130 for easy reference by doctors or managers. The comprehensive health risk evaluation method provided in the embodiment of the present invention has high accuracy and conducts a relatively comprehensive evaluation of patients from multiple dimensions. Even when facing patients with similar health data, it can effectively distinguish and rank them. From the ranking results, doctors and managers can intuitively understand the health risk levels of different patients, providing strong support for subsequent diagnosis and treatment and management decisions.

[0170] 4. Follow-up plan generation

[0171] In order to achieve stratified management of patients, monitor the patient's condition and evaluate the treatment effect, it is necessary to set the follow-up and collection frequency of each risk assessment indicator according to the patient's risk level and personal health status. The doctor or manager obtains the recommended follow-up plan corresponding to patients with different risk levels from the follow-up plan generation module of the cloud service end 140, including follow-up indicators and follow-up frequency. The doctor or manager adjusts the follow-up plan based on the actual situation of the patient, such as the patient's schedule, follow-up willingness, measurement cost, etc., wherein the initial measurement time of each follow-up indicator of the patient is set as the enrollment time. The patient queries his or her follow-up plan through the follow-up plan viewing module of the patient end 120, uploads the indicator monitoring results or completes the follow-up examination according to the recommended indicator collection frequency. The system calculates the next measurement time based on the last measurement time of each indicator of the patient and the corresponding follow-up frequency. After the management cycle ends, the health risk assessment is re-performed according to the follow-up results, and the patient's health risk level is updated.

[0172] (1) Follow-up plan formulation rules:

[0173] The follow-up plan is obtained according to the follow-up plan rule table, which includes indicator categories, follow-up indicators and follow-up frequencies. The follow-up plan is formulated based on the difficulty and cost of indicator measurement, indicator changes, and the patient's health status: compared with patients with lower health risks, patients with higher health risks need to adopt a higher follow-up frequency. For indicators with higher measurement difficulty, higher measurement cost, or less volatility, a lower follow-up frequency is adopted.

[0174] (2) Classification of follow-up indicators:

[0175] The purpose of follow-up is to regularly monitor the health status of patients to conduct health assessment, so the follow-up indicators are all risk assessment indicators. Among them, age, height, medical history, family history and other indicators only need to be collected once when the patient is enrolled, and the remaining risk assessment indicators are collected regularly as follow-up indicators.

[0176] According to the difficulty and cost of indicator measurement, follow-up indicators are divided into basic indicators and additional indicators. Basic indicators refer to indicators with low measurement difficulty and low measurement cost, and are directly related to the patient's health status. Additional indicators refer to indicators with high measurement difficulty and high measurement cost, and change slowly.

[0177] Basic indicators include body weight, blood sugar, exercise time, and dietary intake. The fluctuations of these indicators are directly related to the patient's metabolic health and disease management. They are also suitable for patients to measure independently outside the hospital, are easy to obtain, and are related to the evaluation of management effectiveness. Additional indicators are divided into two categories according to the examination category. One is biochemical indicators, including liver function, blood lipids, kidney function and other indicators related to blood tests; the other is imaging indicators, including liver fat content, fatty liver progression and complications. These indicators are used to evaluate liver health and other metabolic risks, as well as to screen for complications and target organ damage, and are related to the evaluation of disease progression.

[0178] (3) Rules for setting the frequency of follow-up visits:

[0179] The frequency of follow-up is determined according to the category of follow-up indicators and the patient's health risk classification. From the perspective of health risk, the higher the patient's health risk level, the more likely this type of patient is to have a worsening of the disease. Therefore, under the same indicator, the higher the risk level of the patient, the higher the follow-up frequency. From the perspective of indicator category, basic indicators are core indicators that reflect changes in the condition, and have low measurement costs and low measurement difficulty, making them suitable for patients to conduct self-measurements outside the hospital. Additional indicators are used to screen and prevent disease worsening and other complications. They do not fluctuate much in a short period of time, and have high measurement costs and difficulty. Patients are often required to go to the hospital for offline measurements. For imaging indicators in additional indicators, the follow-up frequency needs to refer not only to the patient's risk level, but also needs to be set in combination with the patient's disease progression.

[0180] In the embodiment, according to the follow-up opinions and expert opinions in the clinical management of diabetes and fatty liver, the follow-up indicators and the recommended follow-up frequencies of the indicators at different risk levels are determined. The corresponding relationship between the follow-up frequency and the follow-up indicators is shown in Table 3.

[0181] Table 3 Follow-up rules

[0182]

[0183]

[0184] The specific follow-up methods include a combination of online and offline methods. For example, for basic indicators that are easy to measure, doctors and managers can obtain the latest health data through regular telephone follow-up or through voluntary upload by patients. For follow-up of biochemical indicators and imaging indicators, patients need to go to the hospital for measurement. Through regular follow-up and monitoring, doctors can timely understand the health status of patients and the effect of disease management, further improving management efficiency.

[0185] In summary, a comprehensive health management device for the management of diabetic fatty liver comorbidity, by collecting patient health data and building a comprehensive health risk evaluation model for diabetic fatty liver comorbidity management patients on the cloud service end, can systematically integrate and analyze the multi-dimensional health data of patients, calculate the comprehensive health risk value of patients and sort them by grade, thereby dividing the risk level of patients and achieving a comprehensive and accurate evaluation of the comprehensive health risk of patients. At the same time, the present invention can formulate targeted follow-up plans for patients with different risk levels, ensure that key indicators can be continuously and timely tracked, realize stratified management of patients, and improve the management efficiency of medical staff on patients.

[0186] like Figure 2 As shown, based on the same inventive concept, an embodiment of the present invention also provides a comprehensive health management method for the management of diabetic fatty liver comorbidity, comprising the following steps:

[0187] S1, patients register and upload their health check data to the cloud server.

[0188] Specifically, the health data collection terminal is used to identify the patient's identity and collect the patient's health test data and upload it to the cloud service end. The health test data includes the measurement data required to calculate the risk assessment index.

[0189] S2, using health test data to complete the measurement and calculation of various risk assessment indicators in the dimensions of demography, disease progression and management effectiveness, and obtain the risk score of each indicator.

[0190] Specifically, the cloud server is used to store patient health test data and follow-up plan rules. By building a comprehensive health risk evaluation model, several risk evaluation indicators and their calculation methods are further divided in the dimensions of demography, disease progression and management effect, and the risk evaluation indicator data is calculated based on the health test data and risk evaluation indicators, and the risk score is obtained through grading and scoring.

[0191] S3, calculate the comprehensive health risk value using the risk score of each indicator and then perform patient risk classification.

[0192] Specifically, using the comprehensive health risk evaluation model built on the cloud server, the risk scores of each dimension are weighted and calculated to obtain the health risk scores of each dimension. The health risk scores of each dimension are then weighted and calculated to obtain the patient's comprehensive health risk value. The patient risk is then graded according to the comprehensive health risk values ​​of different patients, including low risk, medium risk and high risk.

[0193] S4, generate a patient follow-up plan based on the follow-up plan rules and patient risk grading.

[0194] Specifically, the cloud service generates a recommended follow-up plan for patients of different risk levels based on the follow-up plan rules, including follow-up indicators and follow-up frequency. The doctor uses the doctor's end to view the patient's risk assessment indicator data, comprehensive health risk value, and risk classification, and adjusts and modifies the patient's follow-up plan based on actual conditions and updates it to the cloud service. The patient uses the patient's end to view the risk assessment indicator data, comprehensive health risk value, risk classification, and adjusted and modified follow-up plan. The patient uploads the indicators in a timely manner according to the follow-up plan, completes the follow-up content, and regularly updates the health risk assessment results.

[0195] It should be noted that the comprehensive health management method for the management of diabetic fatty liver comorbidities and the comprehensive health management device for the management of diabetic fatty liver comorbidities provided in the above-mentioned embodiments belong to the same inventive concept. The specific implementation process is detailed in the embodiment of the comprehensive health management device for the management of diabetic fatty liver comorbidities, which will not be repeated here.

[0196] The specific implementation methods described above provide a detailed description of the technical solutions and beneficial effects of the present invention. It should be understood that the above is only the most preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, supplements and equivalent substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A comprehensive health management device for the management of diabetic fatty liver comorbidity, characterized in that: include: Health data collection terminals, doctor terminals and patient terminals that communicate with the cloud service terminal respectively; The health data collection terminal is used to identify the patient and collect the patient's health test data and upload it to the cloud service end; The cloud service end is used to store patient health test data and follow-up plan rules; it is also used to construct a comprehensive health risk evaluation model, further divide a number of risk evaluation indicators and their calculation methods in the dimensions of demography, disease progression and management effect, and calculate the risk evaluation indicator data based on the health test data and the risk evaluation indicators, and then obtain the risk score by grading and assigning points, and calculate the risk score by multi-dimensional weighted calculation to obtain a comprehensive health risk value, and then perform patient risk grading according to the comprehensive health risk value; It is also used to generate a patient follow-up plan based on follow-up plan rules and patient risk stratification; The doctor end is used to view the patient risk assessment index data, comprehensive health risk value and risk classification, and adjust and modify the patient follow-up plan based on actual conditions and update it to the cloud service end; The patient terminal is used to view risk assessment indicator data, comprehensive health risk values, risk grading, and adjusted follow-up plans, and upload measurement data that needs to be uploaded by the patient in the risk assessment indicators.

2. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 1, characterized in that: The risk assessment indicators and their calculation methods are further divided into several risk assessment indicators and their calculation methods based on the dimensions of demography, disease progression and management effect, including: In the demographic dimension, the risk assessment indicators include: age, body mass index, abdominal obesity, disease history and family history; In terms of disease progression, the risk assessment indicators include: risk level of fatty liver, blood lipid level, renal function level, liver function level, insulin resistance and complications; In terms of management effectiveness, risk assessment indicators include: weight control, blood sugar control, exercise control and diet control.

3. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 2, characterized in that: Calculations of risk factors for age, body mass index, abdominal obesity, medical history, and family history include: Age: The age range is determined based on the patient’s actual age; Body mass index: BMI, BMI = weight (kg) / height 2 (m 2 ), patients were divided into different levels including thin, normal, overweight and obese according to BMI; Abdominal obesity: Use a measuring tool to measure the patient's waist circumference, and determine whether the patient has abdominal obesity based on whether the waist circumference meets the abdominal obesity standard; Medical history: by asking the patient or checking the medical records, find out whether the patient has had any diseases including hypertension, hyperlipidemia, gout, cardiovascular and cerebrovascular diseases and chronic liver disease in the past; Family history: Ask the patient whether there is a history of diseases in his or her family, including liver cancer, cirrhosis, and diabetes.

4. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 2, characterized in that: The calculation methods for the risk of fatty liver, blood lipid levels, kidney function levels, liver function levels, insulin resistance and complications include: Risk level of fatty liver: According to the liver fat content and the degree of liver fibrosis progression, the patient's risk level of fatty liver is divided into low risk, medium risk, high risk and very high risk; Blood lipid level: Blood lipid test results including low-density lipoprotein, triglycerides and total cholesterol are used to determine whether the patient has abnormal blood lipid levels; Renal function level: Blood test results of renal function indicators including uric acid, creatinine and blood urea nitrogen are used to determine whether the patient has abnormal renal function level; Liver function level: The liver function index blood test results including alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase are used to determine whether the patient has abnormal liver function level; Insulin resistance: The insulin resistance index is calculated based on the blood test results of insulin indicators including fasting blood glucose and fasting insulin levels using the formula: fasting blood glucose (mmol / L)*fasting insulin (μU / mL) / 22.

5. The insulin resistance index is used to determine whether the patient has insulin resistance. Complications: By questioning the patient, reviewing medical records or conducting relevant examinations, we can find out whether the patient has complications including cardiovascular and cerebrovascular diseases, diabetic retinopathy and diabetic foot.

5. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 2, characterized in that: The calculation methods for weight control, blood sugar control, exercise control and diet control include: Weight control: Based on the weight measurement data uploaded by the patient in the previous management cycle, the actual weight loss per month is compared with the monthly target weight loss. If the actual weight loss reaches or exceeds the target weight loss, the output is "reached", and if the target weight loss is not reached, the output is "failed". The monthly target weight loss is calculated based on the patient's body mass index, risk level of fatty liver, liver function level and weight. Blood sugar control: Calculate the blood sugar compliance rate based on the blood sugar measurement data uploaded by the patient in the previous management cycle. The blood sugar compliance rate is the ratio of the number of blood sugar compliance times to the total number of blood sugar measurements. If the blood sugar compliance rate reaches or exceeds the preset standard, it is judged that blood sugar control is met. Otherwise, it is judged that blood sugar control is not met. The target blood sugar value for blood sugar compliance includes fasting blood sugar value and random blood sugar value, which are calculated based on the patient's complications and age. Exercise control: Based on the exercise data uploaded by the patient in the previous management cycle, the average daily exercise duration is compared with the daily target exercise duration. If the average daily exercise duration reaches the target exercise duration, the output is "reaching the standard", otherwise, the output is "not reaching the standard". The daily target exercise duration is the ratio of the recommended daily calorie consumption to body weight. The recommended daily calorie consumption is set based on whether there is insulin resistance. Dietary control: Dietary control is measured by the intake compliance rate, that is, the comparison between the average actual daily intake and the target daily intake. If the average actual daily intake is lower than the target daily intake, the output is met; otherwise, the output is not met. The target daily intake is calculated by multiplying the ideal body weight and the calories required per unit body weight. The ideal body weight is set according to height, and the calories required per unit body weight is set according to body mass index.

6. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 1, characterized in that: The risk assessment index data is calculated based on the health test data and risk assessment indicators, and the risk score is obtained by grading and assigning points, including: The health check data of the patients are summarized, and the risk assessment index data is calculated by combining the risk assessment index and its calculation method. The risk assessment index data is graded and scored to obtain the risk score corresponding to each risk assessment index data of each patient.

7. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 1 or 6, characterized in that: The risk score is calculated through multi-dimensional weighted calculation to obtain a comprehensive health risk score, including: After obtaining the risk scores corresponding to all risk assessment indicator data of each patient, the risk scores are weighted and summed according to the dimensions of demography, disease progression and management effect to which the different risk assessment indicator data belong to to obtain the health risk score of each dimension. The calculation formula is as follows: Among them, Score ij represents the health risk score of the jth dimension of the i-th patient, m represents the number of risk assessment indicator data contained in this dimension, and score(k) represents the risk score corresponding to the k-th risk assessment indicator data; Then, the weighted sum of the health risk scores of each dimension is calculated to obtain the comprehensive health risk value. The calculation formula is as follows: Score i =λ1Score i1 +λ2Score i2 +λ3Score i3 Among them, Score i represents the comprehensive health risk value of the i-th patient, Score i1 、Score i2 and Score i3 represent the health risk scores of the i-th patient in the demographic dimension, disease progression dimension, and management effect dimension respectively, and λ1, λ2, and λ3 represent weight values ​​whose sum is 1.

8. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 1 or 7, characterized in that: Patient risk stratification is performed based on comprehensive health risk values, including: The calculated comprehensive health risk values ​​of all patients are sorted according to the scores, and the risk level of each patient is divided into high risk level, medium risk level and low risk level by setting a threshold.

9. The comprehensive health management device for managing diabetic fatty liver comorbidity according to claim 1, characterized in that: Generate a patient follow-up plan based on the follow-up plan rules and patient risk stratification, including: The follow-up plan rules include indicator categories, follow-up indicators and follow-up frequency; among them, indicator categories include basic indicators, biochemical indicators and imaging indicators. The follow-up indicators of basic indicators include body weight, blood sugar, dietary intake and exercise volume. The follow-up indicators of biochemical indicators include blood test-related indicators of liver function, blood lipids and kidney function. The follow-up indicators of imaging indicators include liver fat content, fatty liver progression and complications. The follow-up frequency is set according to different follow-up indicators and patient risk classification to obtain a follow-up plan for each patient.

10. A comprehensive health management method for managing diabetic fatty liver comorbidity, implemented by using the comprehensive health management device for managing diabetic fatty liver comorbidity as claimed in any one of claims 1 to 9, characterized in that: The steps include: Use the health data collection terminal to identify the patient and collect the patient's health test data and upload it to the cloud service end; Use cloud servers to store patient health test data and follow-up plan rules; By constructing a comprehensive health risk evaluation model, several risk evaluation indicators and their calculation methods are further divided in the dimensions of demography, disease progression and management effect. The risk evaluation indicator data is calculated based on the health test data and risk evaluation indicators, and the risk score is obtained by grading and assigning points. The risk score is calculated by multi-dimensional weighted calculation to obtain a comprehensive health risk value, and then the patient risk is graded according to the comprehensive health risk value. Generate patient follow-up plans based on follow-up plan rules and patient risk stratification; Use the doctor's end to view the patient's risk assessment index data, comprehensive health risk value and risk classification, and adjust and modify the patient's follow-up plan based on actual conditions and update it to the cloud service end; Use the patient end to view risk assessment indicator data, comprehensive health risk values, risk grading, and adjusted follow-up plans, and upload measurement data that needs to be uploaded by the patient in the risk assessment indicators.

Citation Information

Cited By

  • Diabetic foot risk assessment method and system based on big data

    CN119132613A